14 -9 (95) 2026 - Ismailova F.Sh. - JIGAR NOALKOGOL YOG' XASTALIGI VA SURUNKALI BUYRAK KASALLIGI: PATOFIZIOLOGIK ALOQA VA KLINIK-LABORATOR MARKERLAR

JIGAR NOALKOGOL YOG' XASTALIGI VA SURUNKALI BUYRAK KASALLIGI: PATOFIZIOLOGIK ALOQA VA KLINIK-LABORATOR MARKERLAR

Ismailova F.Sh. - Abu Ali ibn Sino nomidagi Buxoro davlat tibbiyot instituti

Rezyume

Jigar noalkogol yog' xastaligi (JNAYX) dunyoda har uch kishidan birida uchraydi va surunkali buyrak kasalligi (SBK) rivojlanish xavfini 1,79 barobar oshiradi. Ushbu maqolada 2023-2026 yillar tadqiqotlari asosida JNAYX–SBK aloqasining patofiziologik mexanizmlari (insulinorezistentlik, adiponektin disbalansi, ichak mikrobiotasi, tizimli yallig'lanish) va buyrak zararlanishini erta aniqlashda foydali laborator markerlar (eGFR CKD-EPI 2021, siydik mikroalbumini, sistatin C) tahlil qilingan. JNAYX bemorlarida buyrak skriningini muntazam o'tkazish tavsiya etiladi.

Kalit so'zlar: JNAYX, MASLD, SBK, adiponektin, mikroalbumin, IL-6, eGFR.

First page

120

Last page

123

For citation:Ismailova F.Sh. - JIGAR NOALKOGOL YOG' XASTALIGI VA SURUNKALI BUYRAK KASALLIGI: PATOFIZIOLOGIK ALOQA VA KLINIK-LABORATOR MARKERLAR//New Day in Medicine 9(95)2026 120-123 https://newdayworldmedicine.com/en/new_day_medicine/9-95-2026

ADABIYOTLAR RO’YXATI

1. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. doi:10.1097/HEP.0000000000000004.
2. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.
4. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785-801. doi:10.1016/j.jhep.2020.01.013.
5. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of NAFLD — Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
6. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862-873. doi:10.1016/j.jhep.2017.06.003.
7. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. doi:10.1371/journal.pmed.1001680.
8. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119(9):1787-1798. doi:10.1093/cvr/cvad095.
9. Whaley-Connell A, Sowers JR. Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity? Cardiorenal Med. 2018;8(1):41-49. doi:10.1159/000479801.
10. Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60(3):313-326. doi:10.1016/j.metabol.2010.09.003.

    file

    download